Previous close | 46.15 |
Open | 46.43 |
Bid | 46.39 x 900 |
Ask | 46.41 x 800 |
Day's range | 46.12 - 46.51 |
52-week range | 40.38 - 51.18 |
Volume | |
Avg. volume | 668,338 |
Market cap | 10.564B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 25.08 |
EPS (TTM) | 1.85 |
Earnings date | 24 Apr 2023 - 28 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 54.04 |
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading...
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to honor the Paris Agreement’s climate goals. The SBTi is a global body that enables companies to set ambitious emissions reductions target